The AI agent use cases that work in regulated healthcare share a shape: high-volume, evidence-grounded, structurally repetitive work with a clear quality bar and a qualified person at the end. Evidence synthesis, document assembly, structured extraction, submission screening. The ones that do not work are the ones requiring judgement the institution cannot articulate, or operating over data it has never harmonised.
This article covers where agents are genuinely deployed, where the claims are ahead of the evidence, and how to tell which category a proposed use case falls into. For the deployment context, see enterprise AI agents.
Where agents are working
Evidence synthesis and literature monitoring
The strongest current use case, and the least glamorous. Systematic literature review, ongoing safety literature monitoring, competitive intelligence. Agents handle the search, retrieval, screening and structured extraction; the reviewer adjudicates inclusion and interprets. The realistic gain is on the screening and extraction portion, which is most of the elapsed time in a manual review — not the interpretation.
Value dossier and HTA submission assembly
Market access teams produce the same evidence argument repeatedly across markets. An agent working over a governed evidence base can assemble a market-specific draft from approved source material with citations preserved. The health economist then does what they are for — constructing and defending the argument — rather than reformatting evidence they already know. See AI for market access and HEOR.
Regulatory document drafting, adjacent to the submission
Clinical overviews, health-authority response drafts, CTD module sections. Deployment here is real but the position of the boundary matters enormously. Agents assembling a first draft from approved sources, with every claim traceable, are in production. Agents producing final submitted content without qualified review are not, and should not be.
Pharmacovigilance signal work
Case processing, literature screening for adverse events, and structured extraction from unstructured narratives are high-volume, protocol-driven, and growing faster than headcount. Agents perform well on the extraction and triage portion; causality assessment and signal adjudication stay with qualified assessors.
Health authority submission screening
For regulators rather than sponsors: completeness checking against submission requirements, extraction of structured data from dossiers, cross-referencing claims against supplied evidence, advertisement surveillance. The volume argument is strong — submission volume rises, regulator headcount does not. See AI for government health agencies.
Hospital operational forecasting
Demand forecasting for pharmacy stock, procurement recommendation, disruption monitoring. Different in character from the evidence work — structured numerical data with statistical methods, and the agent's contribution is orchestration and explanation rather than the prediction itself. Worth noting because the return is most directly measurable here, which matters for a first deployment.
Where the claims run ahead
Autonomous clinical decision-making. Marketed, occasionally. Not deployable in any regulated setting the authors are aware of — the regulatory, liability and professional accountability structures require a qualified human decision-maker.
End-to-end submission generation. "Upload your data, receive a submission" is a demonstration, not a deployment. Agents draft components; they do not construct the case.
Agents over unharmonised data. The most common failure, and not a technology failure. If the honest answer to "where does this evidence live and how do we know it is current" is unclear, that is the project, and the agent comes after.
Where Eclypse sits: the same registry of task modules runs across all of the working use cases above — market access, government submission screening, hospital operations, clinical trial pre-screening. See how it plays out in a real deployment in the case studies.
The useful question is not which use cases exist but whether a specific workflow is a candidate — and sometimes the honest answer is no.
Common questions about AI agent use cases in healthcare.
What is the most common AI agent use case in pharma?
Evidence synthesis and literature work — systematic review screening, safety literature monitoring, and structured extraction from publications.
Can AI agents write regulatory submissions?
They can draft components from approved source material with claims traced to evidence. They do not construct the submission strategy or produce final submitted content without qualified review.
What healthcare AI agent use cases should be avoided?
Autonomous clinical decision-making, end-to-end submission generation, and any deployment over data that has not been harmonised and provenance-tracked.
How do you choose a first AI agent use case?
Pick one that is high-volume, evidence-grounded, structurally repetitive, adjacent to the validated estate, and that builds a reusable evidence layer — chosen for learning, not maximum immediate value.
Tell us the workflow — we'll tell you where the handoff belongs, including if it isn't worth automating.
Book a working session
ECLYPSE
AI
Our proprietary AI orchestration platform for healthcare: one engine, a registry of reusable task modules and domain agents, and a governed knowledge base — deployed inside your walls and run by your team.